Mohamed Derbala, MD

1.7K posts

Mohamed Derbala, MD

@MDerbalaMD

Research Scientist, MD Anderson Cancer Center. Tweets are mine.

Houston, TX Katılım Ağustos 2019

264 Takip Edilen393 Takipçiler

Sabitlenmiş Tweet

Mohamed Derbala, MD@MDerbalaMD·2 Eki

Excited to share our latest editorial in @JAMAOnc, bit.ly/4586d1u. As one of the authors, I'm thrilled to explore the forefront of cancer treatment, its promises, and the hurdles we face. @HajjarJoud, @ANaingMD, @PatrickHwuMD, @Dr_R_Kurzrock, @MDAndersonNews, @OncoAlert

English

14.6K

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·4d

Join us April 11th for #IPOF2026, where Dr. James Maher will deliver an update on genitourinary oncology. Don't miss this 1 day event, packed with insights. Meeting website & registration: innovationsjournals.m-pages.com/ipof-2026 #precisiononcology #JIPO #medconference @OncologyNetwork

English

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·2d

Have you read our most recent #JIPO issue yet? Dive into AXL inhibitor oncology clinical trials, high-grade brain tumor treatments, and more: meridian.allenpress.com/innovationsjou… @InnoJournals @OncologyNetwork #oncology #precisiononcology #immunotherapy

English

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·2d

What do clinicians need to know about pulmonary toxicities from ICI therapy? JIPO author Ajay Sheshadri breaks it down in our latest interview. youtube.com/watch?v=VANIZv… #ICI #precisiononcology #JIPO @InnoJournals @OncologyNetwork

YouTube

English

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·5 Mar

We are excited to have Dr. Aung Naing speak at #IPOF2026 on April 11th! He will present on immune checkpoint inhibitors — exploring toxicity, resistance, & biomarker gaps in outcomes & strategies.Registration: innovationsjournals.m-pages.com/ipof-2026 #precisiononcology @OncologyNetwork @AnaingMD

English

161

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·13 Şub

#JIPO special call for papers: #AI in Immunotherapy, Precision Oncology, & Clinical Trials: …ovationsjournals-jipo.kglmeridian.com/page/call-for-… #aioncology @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @OncologyNetwork

English

265

Mohamed Derbala, MD retweetledi

Khin Naing Foundation USA@KhinNaingUSA·9 Şub

Khin Naing Foundation USA is pleased to host Michael Frei, PharmD, Clinical Pharmacy Specialist in the Melanoma & Sarcoma Departments at MD Anderson Cancer Center, for an inspiring session on “The Journey to Becoming a Pharmacist.” 📅 February 21 | 2:00 PM CDT 👉 Register here: knfoundation-usa.com/michael-frei

English

235

Mohamed Derbala, MD retweetledi

Khin Naing Foundation USA@KhinNaingUSA·11 Şub

On 2/7, Khin Naing Foundation proudly sponsored the Youth Entrepreneur Group of Great Houston for their participation in the JA Trade Fair at Memorial City Mall. We congratulate the young entrepreneurs on showcasing GhostChalk at this event organized by JA.

English

109

Mohamed Derbala, MD@MDerbalaMD·30 Oca

Great opportunity!

JIPO Editors@JIPOEditors

There's still time to submit an abstract for #IPOF2026! April 11, 2026 (hybrid). …ovationsjournals-jipo.kglmeridian.com/page/ipof @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @OncologyNetwork @Innovativehci

English

Mohamed Derbala, MD@MDerbalaMD·27 Oca

Phase 2, advanced ACC: single-agent pembrolizumab showed meaningful, durable benefit in a subset with a manageable safety profile.

JIPO Editors@JIPOEditors

Habra et al: "Phase 2 Study of Monotherapy with #Pembrolizumab for Advanced Adrenocortical Carcinoma" doi.org/10.36401/JIPO-… #JIPO #AntiPDL1 #immunotherapy @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @OncologyNetwork

English

161

Mohamed Derbala, MD@MDerbalaMD·27 Oca

Interesting read! New retrospective data comparing haploidentical vs matched-related donor allo-SCT: acute GVHD was more frequent with haplo, while chronic GVHD rates were similar.

JIPO Editors@JIPOEditors

Vargas et al. analyzed development of #GVHD during the 1st year after transplantation doi.org/10.36401/JIPO-… #graftversushost #stemcell #JIPO #transplant @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @OncologyNetwork

English

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·23 Ara

#JIPO case report by Demiray et al. "Exceptional response in a patient with mRCC through precision-guided treatment involving immunotherapy rechallenge with temsirolimus and bevacizumab" doi.org/10.36401/JIPO-… #immunotherapy @OncologyNetwork

English

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·29 Ara

Vargas et al. explores incidence of acute and chronic GVHD and to analyze factors associated with the its development during the first year after transplantation doi.org/10.36401/JIPO-… #graftversushost #stemcell #JIPO #GVHD #transplant @OncologyNetwork

English

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·13 Oca

Rosen et al: Replication-Competent T-SIGn Vectors Allow for Exchange of Transgenes & Viral Persistence doi.org/10.36401/JIPO-… #immunotherapy #solidtumors #JIPO @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @OncologyNetwork

English

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·12 Oca

Submit by 1/31! We're accepting abstracts to be presented at #IPOF2026. …ovationsjournals-jipo.kglmeridian.com/page/ipof @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @OncologyNetwork @Innovativehci #immunotherapy #oncology #JIPO

English

Mohamed Derbala, MD retweetledi

JIPO Editors@JIPOEditors·26 Ara

Registration for #IPOF2026 is now open! Hear the latest in #precisiononcology and cancer management, connect with colleagues and learn new techniques. Saturday, April 11, 2026 Attend in person or online innovationsjournals.m-pages.com/ipof-2026

English

Mohamed Derbala, MD@MDerbalaMD·12 Oca

TLR9 agonist lefitolimod + ipilimumab: well-tolerated, immune-active, clinically modest in advanced solid tumors. Paired biopsies suggest TME conditioning that is worth building on. @MirellaNardo @mgoudaMD @ANaingMD @JIPOEditors

JIPO Editors@JIPOEditors

Nardo et al assess the safety & preliminary efficacy of the combination of #lefitolimod and #ipilimumab in patients with advanced solid tumors doi.org/10.36401/JIPO-… #immunotherapy #checkpointinhibitor #phase1trial #JIPO @DavidHongMD @ANaingMD @OncologyNetwork